Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases

Xing Li, Mingyu Liao, Rufei Shen, Linlin Zhang, Hua Hu, Jun Wu, Xiuli Wang, Hua Qu, Shaodong Guo, Min Long, Hongting Zheng, Xing Li, Mingyu Liao, Rufei Shen, Linlin Zhang, Hua Hu, Jun Wu, Xiuli Wang, Hua Qu, Shaodong Guo, Min Long, Hongting Zheng

Abstract

Asprosin is a white adipose tissue-derived hormone that increases abnormally in mammals with insulin resistance. However, the role of asprosin in polycystic ovary syndrome (PCOS), a disease partly characterized by insulin resistance, and its potential connection with type 2 diabetes mellitus (T2DM) and PCOS has not been thoroughly elucidated to date. To investigate the association of asprosin with metabolic profiles, sex-related hormones, or inflammation in females with T2DM or PCOS, plasma asprosin and metabolic indicators were measured in 66 healthy females, 53 female patients with T2DM, and 41 patients with PCOS. Spearman's correlation analysis and binary logistic regression analysis models were used. Plasma asprosin was significantly higher in T2DM females than in healthy subjects (P < 0.001) and was positively correlated with fasting blood glucose (FBG), hemoglobin A1c (HbA1c), and HOMA-IR (P < 0.05). Asprosin in PCOS subjects was also higher than in healthy subjects (P < 0.001) but lower than in T2DM subjects (P < 0.05), and it was positively correlated with FBG, HbA1c, HOMA-IR, LDL-c, APOB, APOE, and testosterone (P < 0.05). The BMI-categorized subgroups of PCOS subjects also showed correlations of asprosin with metabolic profiles and sex-related hormones. Binary logistic regression analysis revealed that plasma asprosin level acted as an independent risk factor for T2DM or PCOS. These findings suggest the correlation of plasma asprosin level with glucose metabolism, lipid metabolism, sex-related hormones, and inflammation in females, supporting asprosin as a potential predictive factor for females with metabolic-related diseases. This trial is registered with ChiCTR-ROC-17010719.

Figures

Figure 1
Figure 1
Plasma asprosin concentrations in groups and the overweight/obese subgroups. (a) n = 66 healthy, 53 T2DM, and 41 PCOS female subjects. P < 0.0001 compared with the healthy group. No significant difference was found between the T2DM and PCOS groups. (b) n = 82 NW and 78 OW subjects from all groups. (c) n = 49 NW and 17 OW from the healthy group. (d) n = 21 NW and 32 OW from the T2DM group. (e) n = 12 NW and 29 OW from the PCOS group. [Normal weight (NW) was defined as BMI < 24 kg/m2, and overweight/obesity (OW) was defined as BMI ≥ 24 kg/m2]. Data are presented as means ± SD, and unpaired T tests were performed.

References

    1. Defronzo R. A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795. doi: 10.2337/db09-9028.
    1. Czech M. P. Insulin action and resistance in obesity and type 2 diabetes. Nature Medicine. 2017;23(7):804–814. doi: 10.1038/nm.4350.
    1. Kershaw E. E., Flier J. S. Adipose tissue as an endocrine organ. The Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2548–2556. doi: 10.1210/jc.2004-0395.
    1. Piya M. K., McTernan P. G., Kumar S. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. The Journal of Endocrinology. 2013;216(1):T1–T15. doi: 10.1530/JOE-12-0498.
    1. Escobar-Morreale H. F. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology. 2018;14(5):270–284. doi: 10.1038/nrendo.2018.24.
    1. Rosenfield R. L., Ehrmann D. A. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews. 2016;37(5):467–520. doi: 10.1210/er.2015-1104.
    1. Kakoly N. S., Khomami M. B., Joham A. E., et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Human Reproduction Update. 2018;24(4):455–467. doi: 10.1093/humupd/dmy007.
    1. Romere C., Duerrschmid C., Bournat J., et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566–579. doi: 10.1016/j.cell.2016.02.063.
    1. Duerrschmid C., He Y., Wang C., et al. Asprosin is a centrally acting orexigenic hormone. Nature Medicine. 2017;23(12):1444–1453. doi: 10.1038/nm.4432.
    1. Zhang L., Chen C., Zhou N., Fu Y., Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clinica Chimica Acta. 2017 doi: 10.1016/j.cca.2017.10.034.
    1. Zhou B. F., Cooperative Meta-Analysis Group of the Working Group on Obesity in China Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomedical and Environmental Sciences. 2002;15(1):83–96.
    1. Alberti K. G. M. M., Zimmet P. Z., WHO Consultation Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine. 1998;15(7):539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>;2-S.
    1. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Human Reproduction. 2004;19(1):41–47. doi: 10.1093/humrep/deh098.
    1. Albareda M., Rodriguez-Espinosa J., Murugo M., de Leiva A., Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia. 2000;43(12):1507–1511. doi: 10.1007/s001250051561.
    1. Lim S. S., Davies M. J., Norman R. J., Moran L. J. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update. 2012;18(6):618–637. doi: 10.1093/humupd/dms030.
    1. Gambineri A., Pelusi C., Vicennati V., Pagotto U., Pasquali R. Obesity and the polycystic ovary syndrome. International Journal of Obesity. 2002;26(7):883–896. doi: 10.1038/sj.ijo.0801994.
    1. Wu S., Divall S., Nwaopara A., et al. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 2014;63(4):1270–1282. doi: 10.2337/db13-1514.
    1. Lim S. S., Norman R. J., Davies M. J., Moran L. J. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obesity Reviews. 2013;14(2):95–109. doi: 10.1111/j.1467-789X.2012.01053.x.
    1. Nilsson L., Binart N., Bohlooly-Y M., et al. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochemical and Biophysical Research Communications. 2005;331(4):1120–1126. doi: 10.1016/j.bbrc.2005.04.026.
    1. Combs T. P., Berg A. H., Rajala M. W., et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes. 2003;52(2):268–276. doi: 10.2337/diabetes.52.2.268.
    1. Spritzer P. M., Lecke S. B., Satler F., Morsch D. M. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149(5):R219–R227. doi: 10.1530/REP-14-0435.
    1. Keane K. N., Calton E. K., Carlessi R., Hart P. H., Newsholme P. The bioenergetics of inflammation: insights into obesity and type 2 diabetes. European Journal of Clinical Nutrition. 2017;71(7):904–912. doi: 10.1038/ejcn.2017.45.
    1. Wang Y., Qu H., Xiong X., et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm. 2018;2018, article 9471583:7. doi: 10.1155/2018/9471583.
    1. Stepto N. K., Cassar S., Joham A. E., et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reproduction. 2013;28(3):777–784. doi: 10.1093/humrep/des463.
    1. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. International Journal of Obesity. 2007;31:S8–S13. doi: 10.1038/sj.ijo.0803730.
    1. Plymate S. R., Matej L. A., Jones R. E., Friedl K. E. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. The Journal of Clinical Endocrinology & Metabolism. 1988;67(3):460–464. doi: 10.1210/jcem-67-3-460.
    1. Pasquali R., Gambineri A., Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 2006;113(10):1148–1159. doi: 10.1111/j.1471-0528.2006.00990.x.
    1. O’Reilly M. W., Kempegowda P., Walsh M., et al. AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2017;102(9):3327–3339. doi: 10.1210/jc.2017-00947.
    1. O'Reilly M., Gathercole L., Capper F., Arlt W., Tomlinson J. Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome. The Lancet. 2015;385, article S16 doi: 10.1016/S0140-6736(15)60331-2.
    1. Trayhurn P., Bing C., Wood I. S. Adipose tissue and adipokines—energy regulation from the human perspective. The Journal of Nutrition. 2006;136(7):1935S–1939S. doi: 10.1093/jn/136.7.1935S.
    1. Conde J., Scotece M., Gómez R., et al. Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. BioFactors. 2011;37(6):413–420. doi: 10.1002/biof.185.
    1. Phosat C., Panprathip P., Chumpathat N., et al. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study. BMC Endocrine Disorders. 2017;17(1):p. 44. doi: 10.1186/s12902-017-0189-z.
    1. Daniele G., Guardado Mendoza R., Winnier D., et al. The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetologica. 2014;51(1):123–131. doi: 10.1007/s00592-013-0543-1.
    1. Liu C., Feng X., Li Q., Wang Y., Li Q., Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 2016;86:100–109. doi: 10.1016/j.cyto.2016.06.028.
    1. Cimini F. A., Barchetta I., Porzia A., et al. Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. Acta Diabetologica. 2017;54(10):961–967. doi: 10.1007/s00592-017-1039-1.
    1. Liu S. Y., Chen J., Li Y. F. Clinical significance of serum interleukin-8 and soluble tumor necrosis factor-like weak inducer of apoptosis levels in patients with diabetic nephropathy. Journal of Diabetes Investigation. 2018;9(5):1182–1188. doi: 10.1111/jdi.12828.
    1. Choi K. M., Lee J., Lee K. W., et al. Comparison of serum concentrations of C-reactive protein, TNF-α, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Research and Clinical Practice. 2004;64(2):99–106. doi: 10.1016/j.diabres.2003.10.007.
    1. Pereira L., Lee S. Y., Gayraud B., et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(7):3819–3823. doi: 10.1073/pnas.96.7.3819.
    1. Ju X., Ijaz T., Sun H., et al. IL-6 regulates extracellular matrix remodeling associated with aortic dilation in a fibrillin-1 hypomorphic mgR/mgR mouse model of severe Marfan syndrome. Journal of the American Heart Association. 2014;3(1, article e000476) doi: 10.1161/jaha.113.000476.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel